MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare ...(accato bursts or pulses are killed mor...)

Date:3/14/2008

accato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer